These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 16382120)

  • 1. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Reiman R; Felsberg GJ; Tien RD; Bigner SH; Zalutsky MR; Zhao XG; Wikstrand CJ; Pegram CN; Herndon JE; Vick NA; Paleologos N; Fredericks RK; Schold SC; Bigner DD
    Clin Cancer Res; 1996 Jun; 2(6):963-72. PubMed ID: 9816257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
    Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
    Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
    J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
    Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
    J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
    Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
    Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
    Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y; Bullard DE; Humphrey PA; Colapinto EV; Friedman HS; Zalutsky MR; Coleman RE; Bigner DD
    Cancer Res; 1988 May; 48(10):2904-10. PubMed ID: 2452014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
    Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
    J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
    Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
    J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas.
    Quang TS; Brady LW
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):972-5. PubMed ID: 14967458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
    Liersch T; Meller J; Kulle B; Behr TM; Markus P; Langer C; Ghadimi BM; Wegener WA; Kovacs J; Horak ID; Becker H; Goldenberg DM
    J Clin Oncol; 2005 Sep; 23(27):6763-70. PubMed ID: 16170184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
    Akabani G; Cokgor I; Coleman RE; González Trotter D; Wong TZ; Friedman HS; Friedman AH; Garcia-Turner A; Herndon JE; DeLong D; McLendon RE; Zhao XG; Pegram CN; Provenzale JM; Bigner DD; Zalutsky MR
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):947-58. PubMed ID: 10705017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR; Scott AM; Dantis L; Capitelli P; Siler K; Hilton S; Finn RD; Kemeny N; Kelsen D; Kostakoglu L
    J Nucl Med; 1995 Apr; 36(4):586-92. PubMed ID: 7699446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
    McLendon RE; Akabani G; Friedman HS; Reardon DA; Cleveland L; Cokgor I; Herndon JE; Wikstrand C; Boulton ST; Friedman AH; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2007 May; 34(4):405-13. PubMed ID: 17499730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
    Bigner DD; Brown M; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Bigner SH; Zhao XG; Wikstrand CJ; Pegram CN
    J Neurooncol; 1995; 24(1):109-22. PubMed ID: 8523067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.